| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-2018 | |
| Phytochemical name or plant extracts | Trans-nerolidol (NER) | |
| PMID | 28903178 | |
| Literature evidence | BACKGROUND: One approach to improve effect of chemotherapy is combination of classical cytostatic drugs with natural compounds, e. g. sesquiterpenes. | |
| IUPAC name | (6E)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol | |
| Phytochemicals’ class or type of plant extracts | Sesquiterpene | |
| Source of phytochemicals or plant Extracts | Myrica rubra | |
| Geographical availability | China South-Central, China Southeast, Hainan, Japan, Korea, Nansei-shoto, Philippines, Taiwan | |
| Plant parts | Essential oil | |
| Other cancers | Breast cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | 41 μg/ml against MDA-MB-231 35 μg/ml against MCF-7 | |
| Potency | In conclusion, sesquiterpenes CAO and NER increased the efficacy of DOX in breast cancer cells in vitro, but did not improve its effect in vivo, in Ehrlich solid tumor bearing mice. | |
| Cell line/ mice model | MCF-7, MDA-MB-231, Ehrlich solid tumor bearing mice | |
| Additional information | Moreover combination DOX with NER suppressed migration ability in vitro. However, none of tested sesquiterpenes was able to improve DOX accumulation in tumors and DOX-mediated inhibition of tumor growth. | |
| PubChem ID | 5284507 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:585602-1 | |
| Safety | NA |